203 related articles for article (PubMed ID: 22768342)
1. Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
Ammar FF; Abdel-Azeim S; Zargarian L; Hobaika Z; Maroun RG; Fermandjian S
PLoS One; 2012; 7(7):e40223. PubMed ID: 22768342
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.
Arora R; de Beauchene IC; Polanski J; Laine E; Tchertanov L
J Mol Recognit; 2013 Sep; 26(9):383-401. PubMed ID: 23836466
[TBL] [Abstract][Full Text] [Related]
3. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.
Depatureaux A; Quashie PK; Mesplède T; Han Y; Koubi H; Plantier JC; Oliveira M; Moisi D; Brenner B; Wainberg MA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7141-50. PubMed ID: 25224008
[TBL] [Abstract][Full Text] [Related]
5. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
6. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
7. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.
Bera S; Pandey KK; Vora AC; Grandgenett DP
J Mol Biol; 2011 Jul; 410(5):831-46. PubMed ID: 21295584
[TBL] [Abstract][Full Text] [Related]
9. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
[TBL] [Abstract][Full Text] [Related]
12. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
[TBL] [Abstract][Full Text] [Related]
14. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
Savarino A
Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
[TBL] [Abstract][Full Text] [Related]
15. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
[TBL] [Abstract][Full Text] [Related]
16. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.
Carcelli M; Bacchi A; Pelagatti P; Rispoli G; Rogolino D; Sanchez TW; Sechi M; Neamati N
J Inorg Biochem; 2013 Jan; 118():74-82. PubMed ID: 23123342
[TBL] [Abstract][Full Text] [Related]
18. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
[TBL] [Abstract][Full Text] [Related]
19. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
[TBL] [Abstract][Full Text] [Related]
20. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
